Sarepta Therapeutics Inc. (SRPT) Receives “Hold” Rating from SunTrust Banks Inc.
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “hold” rating reiterated by SunTrust Banks Inc. in a report released on Monday. They currently have a $52.00 price target on the stock. SunTrust Banks Inc.’s price objective points to a potential upside of 6.25% from the company’s previous close.
Several other equities research analysts have also commented on SRPT. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 price target on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Jefferies Group set a $58.00 price target on shares of Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday, October 2nd. JMP Securities restated an “underperform” rating and issued a $10.00 price target on shares of Sarepta Therapeutics in a report on Thursday, September 15th. Wedbush restated an “outperform” rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, September 20th. Finally, Piper Jaffray Cos. set a $68.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 4th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $63.31.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 6.39% during mid-day trading on Monday, reaching $48.94. 4,715,756 shares of the company’s stock traded hands. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The firm’s 50-day moving average price is $45.66 and its 200 day moving average price is $26.92. The firm’s market cap is $2.34 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/sarepta-therapeutics-inc-srpt-receives-hold-rating-from-suntrust-banks-inc.html
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the company posted ($0.87) EPS. On average, equities analysts forecast that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In related news, SVP David T. Howton sold 7,000 shares of the stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the sale, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at $1,707,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David T. Howton sold 9,304 shares of the stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares in the company, valued at $558,400. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
A number of hedge funds have recently made changes to their positions in SRPT. Teacher Retirement System of Texas increased its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new position in Sarepta Therapeutics during the second quarter worth $154,000. Quantitative Systematic Strategies LLC bought a new position in Sarepta Therapeutics during the second quarter worth $211,000. BNP Paribas Arbitrage SA boosted its position in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares in the last quarter. Finally, National Planning Corp boosted its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. 65.06% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.